Quantcast
Depression Often Goes Untreated In Parkinsons Patients

Depression Often Goes Untreated In Parkinson's Patients

Rayshell Clapper for redOrbit.com - Your Universe Online On August 11, 2014, people were rocked by the news that Robin Williams had committed suicide by asphyxiation. He hung himself according to one CNN article. For many, the shock was too...

Latest Parkinson's disease Stories

2014-08-21 16:24:23

REHOVOT, Israel, August 21, 2014 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ] Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has signed definitive investment agreements for a $16 million financing round led by certain of its existing investors with the participation of new investors, including The Elias Group. The company plans to use the funding to further the clinical and regulatory...

2014-08-12 08:31:15

NEW YORK, Aug. 12, 2014 /PRNewswire-USNewswire/ -- Research projects from five groups active in Parkinson's research comprise the 2014 first half (1H 2014) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program projects are presented directly to industry groups who may wish to invest in further development. By connecting industry leaders with those studies ripe for investment, the...

2014-08-05 16:27:31

GRAND RAPIDS, Mich., Aug. 5, 2014 /PRNewswire/ -- Van Andel Research Institute (VARI) is scheduled to host Rallying to the Challenge, a meeting which highlights the many ways people with Parkinson's disease can impact the clinical trial process and accelerate access to new Parkinson's disease treatments. http://photos.prnewswire.com/prnvar/20140417/76339 The meeting will take place during the third annual Grand Challenges in Parkinson's Disease symposium, one of the most...

2014-08-05 12:32:03

NEW YORK, Aug. 5, 2014 /PRNewswire-USNewswire/ -- Researchers need to know the genetic profiles of their study participants to understand more about how certain mutations manifest disease. But do the participants have to know? A group of 35 Parkinson's disease (PD) researchers published today in Genetics of Medicine the different answers to that question among sites investigating mutations in the LRRK2 gene, the greatest known genetic contributor to PD. Investigators from The Michael...

2014-08-04 23:09:13

FPRT Bio works closely with academic leaders and research organizations to advance the use of XPro1595 in the treatment of Parkinson’s disease. Dallas, Texas (PRWEB) August 04, 2014 FPRT Bio, a privately held clinical stage biopharmaceutical company, is developing XPro1595, a novel second generation inhibitor of soluble TNF, for the treatment of neurodegenerative diseases including ALS, MS, Parkinson’s and Alzheimer’s diseases. FPRT Bio works closely with academic partners and...

2014-08-04 08:57:44

MPG Max Planck researchers show that two products of the gene DJ-1 can increase the survival of neurons Parkinson’s disease affects neurons in the Substantia nigra brain region – their mitochondrial activity ceases and the cells die. Researchers at the Max Planck Institute of Molecular Cell Biology and Genetics show that supplying D-lactate or glycolate, two products of the gene DJ-1, can stop and even counteract this process: Adding the substances to cultured HeLa cells and to...

2014-08-04 08:27:58

REHOVOT, Israel, August 4, 2014 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ] Ltd. today announced that the European Medicines Agency (EMA) has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa (LD/CD) treatment for advanced Parkinson's disease, eligible for a European Union marketing authorization application procedure ("centralized procedure"). According to EMA guidelines, the EMA can allow products for which the centralized...

2014-07-31 12:29:21

AFFiRiS AG presents Phase I data on a first-of-its-kind treatment with support from The Michael J. Fox Foundation NEW YORK and VIENNA, July 31, 2014 /PRNewswire/ -- AFFiRiS AG announced today at a press conference in New York results of AFF008, a Phase I clinical trial of PD01A, a vaccine against Parkinson's disease. PD01A is the first therapy against the protein alpha-synuclein, a promising Parkinson's drug target, to enter clinical testing. The Michael J. Fox...

2014-07-31 12:29:00

DUBLIN, July 31, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Parkinson's Disease Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Parkinson's disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent...

2014-07-29 08:33:46

VIENNA, July 29, 2014 /PRNewswire/ -- What: AFFiRiS AG, Vienna, Austria will present data from a Phase I clinical trial of PD01A, a vaccine approach that aims to slow or stop Parkinson's disease progression. The Michael J. Fox Foundation supported the study with a $ 1.5 million grant and will discuss the impact of the results for patients and the Parkinson's research community. When: Thursday, July 31, 2014 11.00 am EST (Eastern Standard Time) 03.00 pm UTC...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related